JPWO2015151867A1 - Utilization of yeast extract containing glutathione as a melanin production inhibitor - Google Patents
Utilization of yeast extract containing glutathione as a melanin production inhibitor Download PDFInfo
- Publication number
- JPWO2015151867A1 JPWO2015151867A1 JP2016511540A JP2016511540A JPWO2015151867A1 JP WO2015151867 A1 JPWO2015151867 A1 JP WO2015151867A1 JP 2016511540 A JP2016511540 A JP 2016511540A JP 2016511540 A JP2016511540 A JP 2016511540A JP WO2015151867 A1 JPWO2015151867 A1 JP WO2015151867A1
- Authority
- JP
- Japan
- Prior art keywords
- glutathione
- yeast extract
- melanin production
- yeast
- production inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 107
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 55
- 229960003180 glutathione Drugs 0.000 title claims abstract description 51
- 229940041514 candida albicans extract Drugs 0.000 title claims abstract description 39
- 239000012138 yeast extract Substances 0.000 title claims abstract description 39
- 230000008099 melanin synthesis Effects 0.000 title claims abstract description 31
- 239000003112 inhibitor Substances 0.000 title claims description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 12
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 208000001382 Experimental Melanoma Diseases 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000006364 Torula Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 241000235646 Cyberlindnera jadinii Species 0.000 description 2
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca+2].OP(O)(O)=O.OP(O)(O)=O YYRMJZQKEFZXMX-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- -1 iron ions Chemical class 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 239000006012 monoammonium phosphate Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002426 superphosphate Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【課題】グルタチオンには高いメラニン産生抑制作用や抗酸化作用等様々な美容効果が知られているが、国内では医薬品に分類されており食品としての利用が出来ない。しかしながら、特に最近では食品にそのような機能が求められている。【解決手段】食経験があり、安全性が認められている酵母から抽出したグルタチオン含有酵母抽出物について、マウスＢ１６メラノーマ細胞によるメラニン産生抑制効果を確認したところ、同濃度のグルタチオン単体と比較して、２倍以上の優れたメラニン産生抑制効果が得られることを確認した。【選択図】図１Glutathione has various cosmetic effects such as high melanin production inhibitory action and antioxidant action, but it is classified as a pharmaceutical in Japan and cannot be used as food. However, recently, such functions are required for foods. A glutathione-containing yeast extract extracted from yeast that has been eaten and has been confirmed to be safe has been confirmed to have an inhibitory effect on melanin production by mouse B16 melanoma cells. It was confirmed that an excellent melanin production inhibitory effect of 2 times or more was obtained. [Selection] Figure 1
Description
本発明は、食経験があり安全性が認められている酵母を利用し、菌体培養後に酵母エキスを抽出し、得られた酵母抽出物及びグルタチオンを利用したメラニン産生抑制剤を提供するものである。 The present invention provides a melanin production inhibitor using yeast extract and glutathione obtained by extracting yeast extract after culturing cells using yeast that has food experience and recognized safety. is there.
加齢、ストレス、紫外線暴露などの要因により引き起こされるシミ、シワ、たるみ等の皮膚症状の悪化に対し、肌の美観を美しく保つことは、女性にとって重要な関心事である。このため、皮膚症状の悪化を予防又は改善するための手段を求め、今尚、様々な研究がなされている。特に、シミ、ソバカス、日焼け後の色素沈着等は、皮膚に存在する色素細胞（メラノサイト）の活性化によりメラニン生成が著しく亢進することが原因で起こることが知られている。これらの色素沈着が関係する皮膚症状の悪化を予防又は改善するための素材の一つとしてグルタチオンが知られている。 Keeping the beauty of the skin beautiful against the deterioration of skin symptoms such as spots, wrinkles and sagging caused by factors such as aging, stress and exposure to ultraviolet rays is an important concern for women. For this reason, a means for preventing or improving the deterioration of skin symptoms is sought, and various studies are still being conducted. In particular, it is known that stains, buckwheat, pigmentation after sunburn, and the like occur due to markedly enhanced melanin production due to activation of pigment cells (melanocytes) present in the skin. Glutathione is known as one of the materials for preventing or improving the deterioration of skin symptoms related to pigmentation.
グルタチオンとは、グルタミン酸、システイン、グリシンという３つのアミノ酸が結合したトリペプチドであり、細胞内で活性酸素や過酸化物質から細胞を保護する抗酸化物質としての働きや、異物を細胞外に排出する解毒作用などの生体内で重要な働きを持つ。肌においても、活性酸素はメラニン色素の発生要因となるが、グルタチオンの抗酸化作用によってシミ、色素沈着が抑制されていると考えられている。 Glutathione is a tripeptide in which three amino acids, glutamic acid, cysteine, and glycine are bound. It acts as an antioxidant that protects cells from active oxygen and peroxides in the cell and discharges foreign substances out of the cell. It has important functions in vivo such as detoxification. Even in the skin, active oxygen is a cause of the generation of melanin pigment, but it is considered that stains and pigmentation are suppressed by the antioxidant action of glutathione.
グルタチオンには高いメラニン産生抑制作用や抗酸化作用等様々な美容効果が知られているが、日本では、医薬品に分類されており食品としての利用が出来ない。 Glutathione is known for its various cosmetic effects such as high melanin production inhibitory action and antioxidant action, but in Japan it is classified as a pharmaceutical and cannot be used as food.
本発明は、食品、又は医薬品等として安全性が高く美白効果の優れたメラニン産生抑制剤を提供することを課題とする。 It is an object of the present invention to provide a melanin production inhibitor that is highly safe and excellent in whitening effect as a food or medicine.
このような状況に鑑みて、鋭意研究を重ねた結果、食経験があり安全性が認められているトルラ酵母を利用し、菌体培養後に酵母エキスを抽出し、得られたグルタチオン高含有酵母エキスにグルタチオン単独よりも高いメラニン産生抑制効果が有ることを見出し、本発明を完成させた。 In view of such a situation, as a result of earnest research, the yeast extract was extracted after cell culture using the torula yeast that had food experience and recognized safety, and obtained yeast extract with high glutathione content Was found to have a higher melanin production inhibitory effect than glutathione alone, and the present invention was completed.
すなわち、本発明は、
（１）酵母抽出物及びグルタチオンを含有するメラニン産生抑剤、
（２）（１）に記載のメラニン産生抑剤を含有する飲食品、
（３）（１）に記載のメラニン産生抑剤を含有する化粧品、
（４）（１）に記載のメラニン産生抑剤を含有する医薬品、
を提供するものである。That is, the present invention
(1) A melanin production inhibitor containing yeast extract and glutathione,
(2) A food or drink containing the melanin production inhibitor according to (1),
(3) Cosmetics containing the melanin production inhibitor according to (1),
(4) A pharmaceutical comprising the melanin production inhibitor according to (1),
Is to provide.
食経験があり、安全性が認められているトルラ酵母から抽出したグルタチオン含有酵母抽出物について、マウスＢ１６メラノーマ細胞によるメラニン産生抑制効果を確認したところ、同濃度のグルタチオン単体と比較して、２倍以上の優れたメラニン産生抑制効果が得られることを確認した。 The glutathione-containing yeast extract extracted from Torula yeast that has dietary experience and has been confirmed to be safe has been confirmed to have an inhibitory effect on melanin production by mouse B16 melanoma cells. It was confirmed that the above excellent melanin production inhibitory effect was obtained.
本発明で使用する酵母は、特に制限なく使用できる。例えば、グルタチオンを含有する酵母から抽出すると、酵母抽出物とグルタチオンを含むグルタチオン含有酵母抽出物が得られるため良い。特に好ましい酵母は、一般名トルラ酵母と称されるCandida utilisである。酵母の培養形式は特に制限がないが、一般にバッチ培養、あるいは連続培養のいずれかが用いられる。培地も一般に使用されているものが使用できる。例えば、炭素源として、ブドウ糖、酢酸、エタノール、グリセロール、糖蜜、亜硫酸パルプ廃液等を使用することができる。窒素源としては、尿素、アンモニア、硫酸アンモニウム、塩化アンモニウム、硝酸塩などが使用される。リン酸、カリウム、マグネシウム源も過リン酸石灰、リン酸アンモニウム、塩化カリウム、水酸化カリウム、硫酸マグネシウム、塩化マグネシウム等の通常の工業用原料で良い。その他に、一般的に、亜鉛、銅、マンガン、鉄イオン等の無機塩を添加する。また、ビタミン、アミノ酸、核酸関連物質等を添加することもある。カゼイン、酵母抽出物、肉エキス、ペプトン等の有機物を添加しても良い。培養温度は２１〜３７℃、好ましくは２５〜３４℃で、ｐＨは３．０〜８．０、特に３．５〜７．０が好ましい。培養条件によりアミノ酸や核酸の生産性が変動するため、目的とする酵母抽出物の製品仕様に合わせて条件設定を行う。
The yeast used in the present invention can be used without particular limitation. For example, extraction from a yeast containing glutathione is preferable because a yeast extract and a glutathione-containing yeast extract containing glutathione are obtained. A particularly preferred yeast is Candida utilis, commonly referred to as Torula yeast. The yeast culture format is not particularly limited, but either batch culture or continuous culture is generally used. A medium that is generally used can also be used. For example, glucose, acetic acid, ethanol, glycerol, molasses, sulfite pulp waste liquid and the like can be used as a carbon source. As the nitrogen source, urea, ammonia, ammonium sulfate, ammonium chloride, nitrate or the like is used. Phosphoric acid, potassium, and magnesium sources may be ordinary industrial raw materials such as lime superphosphate, ammonium phosphate, potassium chloride, potassium hydroxide, magnesium sulfate, and magnesium chloride. In addition, generally, inorganic salts such as zinc, copper, manganese, and iron ions are added. In addition, vitamins, amino acids, nucleic acid-related substances, etc. may be added. Organic substances such as casein, yeast extract, meat extract, and peptone may be added. The culture temperature is 21 to 37 ° C., preferably 25 to 34 ° C., and the pH is preferably 3.0 to 8.0, particularly 3.5 to 7.0. Since the productivity of amino acids and nucleic acids varies depending on the culture conditions, conditions are set according to the product specifications of the target yeast extract.
菌体培養後に酵母菌体から抽出を行う。抽出法は、とくに制限がないが、一般的に、自己消化法、熱水抽出法、酵素抽出法、酸、若しくはアルカリ抽出法、又はこれらの組み合わせにより行うことが可能である。 Extraction is performed from yeast cells after cell culture. The extraction method is not particularly limited, but can generally be performed by an autolysis method, a hot water extraction method, an enzyme extraction method, an acid or alkali extraction method, or a combination thereof.
自己消化により抽出する場合は、例えば、５５℃で４時間攪拌する。酵素抽出法であれば、細胞壁溶解酵素又はプロテアーゼ等で攪拌抽出する。酸抽抽出法であれば、硫酸等で酸性に調整後、抽出する。アルカリ抽出法であれば、アルカリに調整後、抽出する。自己消化後（例えば５５℃で４時間攪拌）に、酵素抽出をする等の組み合わせも可能である。 When extracting by autolysis, it stirs at 55 degreeC for 4 hours, for example. In the case of an enzyme extraction method, stirring and extraction is performed with a cell wall lytic enzyme or a protease. In the case of the acid extraction method, extraction is performed after acidification with sulfuric acid or the like. If it is an alkali extraction method, it will extract after adjusting to an alkali. Combinations such as enzyme extraction after self-digestion (for example, stirring at 55 ° C. for 4 hours) are also possible.
抽出後は遠心分離で酵母残渣を分離し、濃縮後、凍結乾燥又は熱風乾燥することでグルタチオン含有酵母抽出物を得ることが出来る。酵母抽出物中に含まれるグルタチオンは、還元型グルタチオン、酸化型グルタチオン、及びこれらの混合物の何れでも良い。酵母抽出物中のグルタチオン含量は、酵母抽出物中にグルタチオンが含まれていればよい。例えば、グルタチオンを３質量％以上、好ましくは１０質量％以上含有する酵母抽出物である。さらに好ましくは、乾燥酵母抽出物中でグルタチオンを１５質量％以上含有する酵母抽出物である。酵母抽出物中のグルタチオン含量が１５％以上となるためには、培養酵母中のグルタチオン含量ができるだけ高いものから、前述の抽出法により酵母抽出物を抽出する方が効率がよい。酵母中のグルタチオン含量を高める方法としては、公知の方法で良い。例えば、培地中に亜鉛イオンを添加する方法（特開２０００−２７９１６４号公報）、カドミウム耐性、マクロライド系抗生物質耐性を指標としたグルタチオン高含有酵母株の取得方法（特開２００６−４２６３７号公報、特開２００６−４２６３８号公報）がある。特開２０１１−１０３７８９号公報のように変異酵母菌体から抽出することでも得ることができる。また、一般に販売されている酵母抽出物を使用することもできる。例えば、興人ライフサイエンス社製の「ハイチオンエキス」ＹＨ−１５、ＹＨ−Ｄ１８等がある。 After extraction, the yeast residue is separated by centrifugation, and after concentration, freeze-dried or hot-air dried to obtain a glutathione-containing yeast extract. The glutathione contained in the yeast extract may be any of reduced glutathione, oxidized glutathione, and a mixture thereof. The glutathione content in the yeast extract may be such that glutathione is contained in the yeast extract. For example, yeast extract containing 3% by mass or more, preferably 10% by mass or more of glutathione. More preferably, the yeast extract contains 15% by mass or more of glutathione in the dry yeast extract. In order for the glutathione content in the yeast extract to be 15% or more, it is more efficient to extract the yeast extract by the above-described extraction method from those having the highest glutathione content in the cultured yeast. As a method for increasing the glutathione content in yeast, a known method may be used. For example, a method for adding zinc ions to the medium (Japanese Patent Laid-Open No. 2000-279164), a method for obtaining a yeast strain with a high glutathione content using cadmium resistance and macrolide antibiotic resistance as indices (Japanese Patent Laid-Open No. 2006-42637) JP, 2006-42638, A). It can also be obtained by extracting from mutant yeast cells as in JP 2011-103789 A. Moreover, the yeast extract currently marketed can also be used. For example, “Hythion extract” YH-15, YH-D18, etc. manufactured by Kojin Life Science Co., Ltd. are available.
グルタチオン濃度の測定方法は、DTNB-HPLC法（Journal of Chromatography,194(1980)424-428）で行った。本願のグルタチオン含量は、還元型及び酸化型グルタチオンを合わせた総グルタチオン含量をいう。
The glutathione concentration was measured by the DTNB-HPLC method (Journal of Chromatography, 194 (1980) 424-428). The glutathione content of the present application refers to the total glutathione content of the combined reduced and oxidized glutathione.
本発明は、酵母抽出物中の成分とグルタチオンの相乗効果であるため、グルタチオン含有量が低い又は、グルタチオンが含まない酵母抽出物にグルタチオンを添加することでもグルタチオン含有酵母抽出物とすることができる。 Since the present invention is a synergistic effect of the components in the yeast extract and glutathione, the glutathione-containing yeast extract can be obtained by adding glutathione to a yeast extract having a low glutathione content or not containing glutathione. .
本発明は、上記した本発明のグルタチオン高含有酵母抽出物を含有することを特徴とする飲食品、化粧品、皮膚外用剤又は医薬品を提供するものである。 This invention provides the food-drinks, cosmetics, the skin external preparation, or a pharmaceutical characterized by containing the above-mentioned glutathione-rich yeast extract of this invention.
本発明における飲食品とは、上記組成物を配合した、食料品、飲料品、嗜好品、サプリメント等、経口で摂取するものを指す。その形態は特に限定されるものではなく、パン類、麺類等主菜となりうるもの、チーズ、ハム、ウインナー、魚介加工品等副菜となりうるもの、果汁飲料、炭酸飲料、乳飲料等の飲料、クッキー、ケーキ、ゼリー、プリン、キャンディー、ヨーグルト等の嗜好品等とすることができる。また、サプリメントとしての形態も特に限定されるものではなく、錠剤、カプセル、ソフトカプセル、栄養ドリンク状の形態をとることもできる。 The food and drink in the present invention refers to foods, beverages, luxury products, supplements, and the like that are ingested orally, in which the above composition is blended. The form is not particularly limited, and can be a main dish such as breads and noodles, can be a side dish such as cheese, ham, wiener, processed seafood, beverages such as fruit juice drinks, carbonated drinks, milk drinks, Favorable items such as cookies, cakes, jelly, pudding, candy, and yogurt can be used. Moreover, the form as a supplement is not specifically limited, It can also take the form of a tablet, a capsule, a soft capsule, and an energy drink form.
飲食品における上記組成物の配合量はメラニン産生抑制効果を有する限り特に限定されるものではなく、例えばグルタチオン含有酵母抽出物が飲食品の質量１００ｇに対し１０ｐｇ〜２０ｇ含まれていればよい。中でも１００ｐｇ〜２ｇが好適であり、１０ｎｇ〜５００ｍｇは更に好適である。 The blending amount of the composition in the food or drink is not particularly limited as long as it has a melanin production inhibitory effect. For example, the glutathione-containing yeast extract may be contained in an amount of 10 pg to 20 g with respect to 100 g of the food or drink. Among them, 100 pg to 2 g is preferable, and 10 ng to 500 mg is more preferable.
本発明の化粧品とは、上記組成物を配合した化粧水、乳液、ファンデーション、口紅などを指す。 The cosmetics of the present invention refer to lotions, emulsions, foundations, lipsticks and the like containing the above composition.
組成物の配合量は特に限定されるものではなく、例えば上記組成物の質量１００ｇに対し１０ｐｇ〜２０ｇ含まれていればよい。中でも１００ｐｇ〜２ｇが好適であり、１０ｎｇ〜５００ｍｇは更に好適である。 The compounding quantity of a composition is not specifically limited, For example, 10pg-20g should just be contained with respect to 100g of mass of the said composition. Among them, 100 pg to 2 g is preferable, and 10 ng to 500 mg is more preferable.
また本発明は、皮膚外用剤などの医薬品として使用することができる。上記組成物を配合したローション、クリーム、軟膏、スプレー、貼付剤（材）などの形状のものを指すが、その形態は特に限定されるものではなく、本発明の目的とする効果を発揮しうるものであればいかなる形態でもかまわない。 Moreover, this invention can be used as pharmaceuticals, such as a skin external preparation. Although it refers to the shape of lotions, creams, ointments, sprays, patches (materials), etc., blended with the above composition, the form is not particularly limited and can exert the intended effect of the present invention. Any form can be used.
医薬品における組成物の配合量は特に限定されるものではなく、例えばグルタチオン高含有酵母抽出物が組成物の質量１００ｇに対し１０ｐｇ〜２０ｇ含まれていればよい。中でも１００ｐｇ〜２ｇが好適であり、１０ｎｇ〜５００ｍｇは更に好適である。
The compounding quantity of the composition in a pharmaceutical is not specifically limited, For example, the glutathione high content yeast extract should just be contained 10pg-20g with respect to 100g of mass of a composition. Among them, 100 pg to 2 g is preferable, and 10 ng to 500 mg is more preferable.
以下に、実施例を挙げて本発明を更に詳細に説明するが、本発明はこれら実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples.
（実施例１）
グルタチオン含有酵母抽出物の製造
（酵母の培養）
キャンディダ・ウチリスＣＳ７５２９株（ＦＥＲＭＰ−３３４０）を予めＹＰＤ培地（酵母エキス１％、ポリペプトン２％、グルコース２％）を含む三角フラスコで種母培養し、これを３０Ｌ容発酵槽に１８Ｌ培地に１〜２％植菌した。培地組成は、グルコース４％、燐酸一アンモニウム０．３％、硫酸アンモニウム０．１６１％、塩化カリウム０．１３７％、硫酸マグネシウム０．０８％、硫酸銅１．６ｐｐｍ、硫酸鉄１４ｐｐｍ、硫酸マンガン１６ｐｐｍ、硫酸亜鉛１４ｐｐｍを用いた。培養条件は、ｐＨ４．０、培養温度３０℃、通気量１ｖｖｍ、撹拌６００ｒｐｍで行い、アンモニアを添加しｐＨのコントロールを行った。１６時間菌体培養した後、培養液を回収し、遠心分離により集菌し、１８０ｇの湿潤酵母菌体を得た。Example 1
Production of yeast extract containing glutathione (culture of yeast)
Candida utilis CS7529 strain (FERMP-3340) is pre-cultured in an Erlenmeyer flask containing YPD medium (yeast extract 1%, polypeptone 2%, glucose 2%) in advance, and this is added to a 30 L fermentor in an 18 L medium. ~ 2% inoculated. Medium composition is 4% glucose, 0.3% monoammonium phosphate, 0.161% ammonium sulfate, 0.137% potassium chloride, 0.08% magnesium sulfate, 1.6 ppm copper sulfate, 14 ppm iron sulfate, 16 ppm manganese sulfate, 14 ppm of zinc sulfate was used. The culture conditions were pH 4.0, culture temperature 30 ° C., aeration rate 1 vvm, stirring 600 rpm, and ammonia was added to control the pH. After culturing the cells for 16 hours, the culture solution was collected and collected by centrifugation to obtain 180 g of wet yeast cells.
（酵母抽出物の抽出）
菌体培養後の湿潤酵母菌体を蒸留水に懸濁して遠心分離を繰り返すことで洗浄した。洗浄後は湿潤菌体を蒸留水に再度懸濁するか、凍結乾燥または熱風乾燥させた乾燥菌体を蒸留水に懸濁し、以下の条件に調整することで抽出物抽出を行った。
自己消化： １Ｎ ＨＣｌでｐＨ５．０に調整後、５５℃で４時間攪拌
酵素抽出： １Ｎ ＮａＯＨでｐＨ７に調整後、細胞壁溶解酵素（ツニカーゼ）或いはプロテアーゼで５５℃、４時間攪拌抽出
酸抽出： １Ｎ硫酸でｐＨ２以下に調整後、６５℃で２分間攪拌抽出
アルカリ抽出：２Ｎ ＮａＯＨでｐＨ１３に調整後、７０℃で２０分間攪拌抽出(Extraction of yeast extract)
The wet yeast cells after cell culture were suspended in distilled water and washed by repeated centrifugation. After washing, the wet cells were suspended again in distilled water, or the dried cells freeze-dried or hot-air dried were suspended in distilled water, and the extract was extracted by adjusting to the following conditions.
Self-digestion: Adjust to pH 5.0 with 1N HCl and stir enzyme extraction at 55 ° C. for 4 hours: Adjust to pH 7 with 1N NaOH, then stir to extract with cell wall lytic enzyme (tunicase) or protease at 55 ° C. for 4 hours. Acid extraction: 1N Adjust to pH 2 or lower with sulfuric acid, then extract with stirring at 65 ° C for 2 minutes. Extraction with alkali: Adjust to pH 13 with 2N NaOH, then extract with stirring at 70 ° C for 20 minutes
（酵母抽出物の乾燥）
抽出後は遠心分離で酵母残渣を分離し、抽出物を濃縮後、凍結乾燥又は熱風乾燥することでグルタチオン含有酵母抽出物を得た。還元型グルタチオン含量は、１５．５１％で、グルタチオン含量（総グルタチオン含量）は、１７．６８％であった。
(Drying yeast extract)
After extraction, the yeast residue was separated by centrifugation, the extract was concentrated, and freeze-dried or hot-air dried to obtain a glutathione-containing yeast extract. The reduced glutathione content was 15.51%, and the glutathione content (total glutathione content) was 17.68%.
（メラニン産生抑制効果の確認）
以下の手順に従ってメラニン産生抑制効果を測定した。(Confirmation of melanin production inhibitory effect)
The melanin production inhibitory effect was measured according to the following procedure.
＜メラニン産生抑制効果の検証＞
Ｂ１６マウスメラノーマ細胞を６ｗｅｌｌ ｐｌａｔｅに播種（２×１０４／ｗｅｌｌ）し、２４時間前培養した（５％ＣＯ２ 、３７℃）。培養液は、５％牛胎児血清を含むＤ−ＭＥＭ培地を使用した。その後、グルタチオン（比較例１）、グルタチオン高含有酵母抽出物実施例１を還元型グルタチオン換算で最終濃度が１．０ｍＭ及びメラニン産生抑制効果が既知となっている乳酸ナトリウム（比較例２）を最終濃度が５０ｍＭとなるように添加した新鮮な培地に置換した。播種４日目に培地を除去し、プレートをＰＢＳ（リン酸緩衝生理食塩水）で洗浄後、０.２５％トリプシンＥＤＴＡで剥がし、遠心（１００００ｒｐｍ、３ｍｉｎ）操作によりペレット（細胞）を回収した。回収したペレットはＰＢＳで２回洗ったのち、１ｍＬのＰＢＳで細胞浮遊液を調整して０．８ｍＬをメラニン量の測定に、０．２ｍＬをタンパク質の定量に使用した。
メラニン量の測定用に回収したペレットを１５０μＬの１Ｎ ＮａＯＨで融解し（１００℃、１０分）、マイクロプレートリーダーを用いて４０５ｎｍの吸光度を測定した。タンパク質の定量用に回収したペレットはＢＣＡ法にてタンパク質の定量を行った。水を添加したものをコントロールとし、コントロールを１００％としてときの比較例１、２を添加して培養した細胞のタンパク質あたりのメラニン量をメラニン生成率として求めた。<Verification of melanin production inhibitory effect>
B16 mouse melanoma cells were seeded (2 × 10 4 / well) on a 6-well plate and pre-cultured for 24 hours (5% CO 2 , 37 ° C.). As the culture solution, D-MEM medium containing 5% fetal bovine serum was used. Thereafter, glutathione (Comparative Example 1), glutathione-rich yeast extract Example 1 was converted to reduced glutathione in a final concentration of 1.0 mM and sodium lactate (Comparative Example 2) whose melanin production inhibitory effect was known. The medium was replaced with fresh medium added to a concentration of 50 mM. On day 4 after seeding, the medium was removed, the plate was washed with PBS (phosphate buffered saline), peeled off with 0.25% trypsin EDTA, and pellets (cells) were collected by centrifugation (10000 rpm, 3 min). The collected pellet was washed twice with PBS, and the cell suspension was adjusted with 1 mL of PBS, and 0.8 mL was used for melanin measurement and 0.2 mL was used for protein quantification.
The pellets collected for measuring the amount of melanin were melted with 150 μL of 1N NaOH (100 ° C., 10 minutes), and the absorbance at 405 nm was measured using a microplate reader. The pellet collected for protein quantification was subjected to protein quantification by the BCA method. The amount of melanin per protein of cells cultured by adding Comparative Examples 1 and 2 when the water was added as a control and the control as 100% was determined as the melanin production rate.
実施例１の結果を図１に示す。図１に示すように、グルタチオン単独（比較例１）ではメラニン産生抑制率がコントロールと比較して約４０％であるのに対して、本願発明のグルタチオン高含有酵母抽出物ではメラニン産生抑制率はコントロールと比較して約８５％であり、グルタチオン単独と比較して２倍以上のメラニン産生抑制効果を有することが判る。これは、グルタチオンが酵母抽出物中のグルタチオン以外の成分と相乗効果を示しているためであると思われる。したがって、本発明におけるグルタチオン高含有酵母抽出物は食品として使用出来、且つ優れたメラニン産生抑制効果を発揮し、メラニン産生抑制剤として有用である。 The results of Example 1 are shown in FIG. As shown in FIG. 1, glutathione alone (Comparative Example 1) has a melanin production inhibition rate of about 40% compared to the control, whereas the glutathione-rich yeast extract of the present invention has a melanin production inhibition rate of It is about 85% as compared with the control, and it can be seen that it has a melanin production inhibitory effect twice or more as compared with glutathione alone. This seems to be because glutathione shows a synergistic effect with components other than glutathione in the yeast extract. Therefore, the glutathione-rich yeast extract in the present invention can be used as a food, exhibits an excellent melanin production inhibitory effect, and is useful as a melanin production inhibitor.
符号の説明
１ コントロール
２ グルタチオン
３ 本願発明（グルタチオン含有酵母抽出物）
４ ポジティブコントロール（乳酸ナトリウム）DESCRIPTION OF SYMBOLS 1 Control 2 Glutathione 3 Invention of the present application (Yeast extract containing glutathione)
4 Positive control (sodium lactate)
Claims (4)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014070964 | 2014-03-31 | ||
| JP2014070964 | 2014-03-31 | ||
| PCT/JP2015/058510 WO2015151867A1 (en) | 2014-03-31 | 2015-03-20 | Use of yeast extract including glutathione as melanin production inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2015151867A1 true JPWO2015151867A1 (en) | 2017-04-13 |
Family
ID=54240197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511540A Pending JPWO2015151867A1 (en) | 2014-03-31 | 2015-03-20 | Utilization of yeast extract containing glutathione as a melanin production inhibitor |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2015151867A1 (en) |
| TW (1) | TWI670016B (en) |
| WO (1) | WO2015151867A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7089305B1 (en) * | 2021-04-15 | 2022-06-22 | 株式会社ファーマフーズ | Skin whitening composition |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000060482A (en) * | 1998-06-11 | 2000-02-29 | Fancl Corp | Food composition |
| JP2001354570A (en) * | 2000-06-15 | 2001-12-25 | Ichimaru Pharcos Co Ltd | Immunoactivating agent and cosmetic using the same |
| JP2002020300A (en) * | 2000-07-07 | 2002-01-23 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
| JP2003252742A (en) * | 2002-02-28 | 2003-09-10 | Kose Corp | Melanocyte dendrite formation inhibitor and skin care preparation containing the same |
| JP2006347988A (en) * | 2005-06-20 | 2006-12-28 | Pola Chem Ind Inc | Cosmetics containing natural yeast extract |
| JP2006347975A (en) * | 2005-06-17 | 2006-12-28 | Bio Solutions:Kk | Oral composition for cardiovascular disease prophylaxis and amelioration |
| JP2008074727A (en) * | 2006-09-19 | 2008-04-03 | Arimino Kagaku Kk | Composition for removing active oxygen radical, and active oxygen radical remover for hair containing the same |
| JP2008303180A (en) * | 2007-06-08 | 2008-12-18 | Noevir Co Ltd | Skin-lightening agent, skincare preparation for external use, and functional oral composition |
| JP2009107962A (en) * | 2007-10-29 | 2009-05-21 | Asahi Breweries Ltd | Yeast extract-containing composition |
| CN102008426A (en) * | 2009-09-08 | 2011-04-13 | 上海利盛生化有限公司 | Cosmetic composition with function of eliminating free radical |
| WO2011118807A1 (en) * | 2010-03-26 | 2011-09-29 | アサヒビール株式会社 | Method for culturing yeast |
-
2015
- 2015-03-20 WO PCT/JP2015/058510 patent/WO2015151867A1/en active Application Filing
- 2015-03-20 JP JP2016511540A patent/JPWO2015151867A1/en active Pending
- 2015-03-27 TW TW104109904A patent/TWI670016B/en active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000060482A (en) * | 1998-06-11 | 2000-02-29 | Fancl Corp | Food composition |
| JP2001354570A (en) * | 2000-06-15 | 2001-12-25 | Ichimaru Pharcos Co Ltd | Immunoactivating agent and cosmetic using the same |
| JP2002020300A (en) * | 2000-07-07 | 2002-01-23 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
| JP2003252742A (en) * | 2002-02-28 | 2003-09-10 | Kose Corp | Melanocyte dendrite formation inhibitor and skin care preparation containing the same |
| JP2006347975A (en) * | 2005-06-17 | 2006-12-28 | Bio Solutions:Kk | Oral composition for cardiovascular disease prophylaxis and amelioration |
| JP2006347988A (en) * | 2005-06-20 | 2006-12-28 | Pola Chem Ind Inc | Cosmetics containing natural yeast extract |
| JP2008074727A (en) * | 2006-09-19 | 2008-04-03 | Arimino Kagaku Kk | Composition for removing active oxygen radical, and active oxygen radical remover for hair containing the same |
| JP2008303180A (en) * | 2007-06-08 | 2008-12-18 | Noevir Co Ltd | Skin-lightening agent, skincare preparation for external use, and functional oral composition |
| JP2009107962A (en) * | 2007-10-29 | 2009-05-21 | Asahi Breweries Ltd | Yeast extract-containing composition |
| CN102008426A (en) * | 2009-09-08 | 2011-04-13 | 上海利盛生化有限公司 | Cosmetic composition with function of eliminating free radical |
| WO2011118807A1 (en) * | 2010-03-26 | 2011-09-29 | アサヒビール株式会社 | Method for culturing yeast |
Non-Patent Citations (3)
| Title |
|---|
| "美容食品素材の市場動向", 食品と開発 ８月号, vol. 39, no. 8, JPN6019037559, 1 August 2004 (2004-08-01), pages 43 - 49, ISSN: 0004418748 * |
| HIRANO, K. ET AL.: "Metabolites produced by yeast and the other microbes and their physiological function.", FRAGRANCE JOURNAL, vol. 20, no. 3, JPN6015033384, 1992, pages 18 - 21, ISSN: 0004418746 * |
| 小西享 他: "酵母エキスの開発と展開", 月刊フードケミカル, vol. 17, no. 10, JPN6016032488, 2001, pages 55 - 60, ISSN: 0004418747 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015151867A1 (en) | 2015-10-08 |
| TW201620396A (en) | 2016-06-16 |
| TWI670016B (en) | 2019-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Growth and bioactive peptides production potential of Lactobacillus plantarum strain C2 in soy milk: A LC-MS/MS based revelation for peptides biofunctionality | |
| Schmacht et al. | Microbial production of glutathione | |
| JP4897229B2 (en) | Maillard reaction inhibitor | |
| JP4854199B2 (en) | Functional material obtained by re-fermenting liquefied sake lees | |
| WO2010071132A1 (en) | Peptide for inhibiting skin aging | |
| JP5967754B2 (en) | Usage of yeast extract extraction residue | |
| CN114945677A (en) | Nicotinamide ribose-producing lactic acid bacterium, and nicotinamide mononucleotide and nicotinamide ribose-producing lactic acid bacterium | |
| TW200621170A (en) | 5'-ribonucleotide-rich yeast extract and its production | |
| RU2556375C1 (en) | Protein having activity against elongation stimulation of fatty acid chains, encoding its gene and their application | |
| JP6172700B2 (en) | Use of Torula yeast-derived glucosylceramide as a fibroblast growth promoter | |
| JP2014088340A (en) | Use of glucosylceramide from torula yeast as skin lightening preparation | |
| TWI767387B (en) | Use of red grape fermented liquid for manufacturing of a composition for improving skin condition and reducing skin pores | |
| AU2020374138B2 (en) | Yeast Strain Producing Glutathione And Method Of Producing Glutathione Using The Same | |
| WO2015151867A1 (en) | Use of yeast extract including glutathione as melanin production inhibitor | |
| JP2009298738A (en) | External preparation for skin | |
| JP2006076927A (en) | Fermented material obtained from mango | |
| JP6261031B2 (en) | Use of Torula yeast-derived glucosylceramide as a colon cancer inhibitor | |
| KR100680580B1 (en) | Method for producing selenium peptide by yeast aytolysis | |
| JP6629512B2 (en) | Composition for promoting collagen production containing glucosylceramide derived from Torula yeast | |
| KR20180067897A (en) | Method for producing quinoa microbial fermentation rich in l-carnitine | |
| JP7029825B2 (en) | Method for Producing Ceramide-Containing Composition | |
| RU2800992C1 (en) | Glutathione-producing yeast strain and a method of producing glutathione using the same | |
| BR112022008206B1 (en) | GLUTATHIONE-PRODUCING STRAIN OF SACCHAROMYCES CEREVISIAE, METHOD FOR PRODUCING GLUTATHIONE, METHOD FOR PREPARING A COMPOSITION INCLUDING GLUTATHIONE, COMPOSITION AND USES THEREOF | |
| Pawlikowska et al. | Lysates of Metschnikowia yeast with higher content of hydroxyproline | |
| JPWO2006095764A1 (en) | UV sensitivity suppressor for skin and functional food and drink |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191008 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200130 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20200130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200901 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200901 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200930 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201104 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201106 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20201225 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20210104 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210617 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20210921 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20211214 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20220112 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20220112 |